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Numerous compounds are widely distributed in nature and many of these possess 
medicinal/biological/pharmacological activity. Curcumin, a polyphenol derived from the 
rhizomes (underground stems) of Curcuma longa Linn (a member of the ginger family, 
commonly known as turmeric) is a culinary spice and therapeutic used in India for 
thousands of years to induce color and flavor in food as well as to treat a wide array of 
diseases. The origin of turmeric as spice and folklore medicine is so old that it is lost in 
legend. Curcumin has many beneficial pharmacological effects which includes, but are 
not limited with, antimicrobial, anti-inflammatory, antioxidant, antiviral, antiangiogenic, 
and antidiabetic activities. Most importantly curcumin possesses immense 
antitumorigenic effect. It prevents tumor formation in a number of animal models, 
including models of lung, liver, stomach, colon, breast, esophageal cancer etc. A concise 
discussion regarding the effects of curcumin on five leading cancers with respect to 
cancer mortality (lung, liver, stomach, colorectal and breast) and associated molecular 
mechanisms is included. The potential applications of curcumin as chemopreventive 
agent, chemosensitizer, and radiosensitizer in both in vitro and in vivo studies have 
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discussed in this chapter. In addition to natural drugs, a large number of synthetic drugs 
(mainly organic and organometallic) are being used as medicines against cancer. 
Synergistic role of two or more drugs against any particular disease plays an important 
role in modern drug discovery research. Subsequently, preclinical and clinical studies of 
drug synergy have become an intriguing part of translational research. 
This chapter describes the pertinent recent examples of synergistic role of curcumin 
with various other molecules with special emphasis to commercial drugs and natural 
products. Curcumin has also demonstrated the ability to improve patient outcomes in 
clinical trials. 
 
Keywords: Cancer, Carcinoma, Adenocarcinoma, Sarcoma, Neoplasm, Apoptosis, 
Angiogenesis, Cell death, Tumor, Toxicity, Carcinogenesis, Drug synergy, Synergistic 
effect, Natural products, Heterocycles, Medicinal chemistry, Pharmacophore, 





3'-UTR  Three prime untranslated region 
8-OHdG  8-Hydroxy-2′-deoxyguanosine 
ACEI  Angiotensin converting enzyme inhibitor 
AFM  Atomic force microscopy 
AIN  American Institute of Nutrition 
ALDH  Aldehyde dehydrogenase 
AMP  Adenosine 5ꞌ-monophosphate 
AMPK  Adenosine 5ꞌ-monophosphate (AMP)-activated  
protein kinase 
Apaf-1  Apoptosis protease-activating factor-1 
ARNT  Aryl hydrocarbon receptor nuclear translocator 
ATG5  Autophagy protein 5 
Bak   Bcl-2-antagonist/killer 
Bax   B-cell lymphoma-2-associated X protein 
Bcl- XL  B-cell lymphoma-extra large 
Bcl-2  B-cell lymphoma-2 
Bcl-Xs  B-cell lymphoma-extra small 
BRCA1  Breast cancer 1, early onset 
CAF  Cancer-associated fibroblasts 
CDK  Cyclin-dependent kinase 
Chk1  Checkpoint kinase 1 
CHOP CCAAT/enhancer binding protein homologous protein 
COX-2  Cyclooxygenase-2 
CTNND1  Catenin delta-1 
CTTN  Cortactin 
CXCL1  Chemokine (C-X-C motif) ligand 1 
DCLK1  Doublecortin-like kinase 1 
DEN  Diethylnitrosamine 
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DIABLO Direct inhibitor of apoptosis protein-binding protein with low 
isoelectric point 
EGCG  (-)-Epigallocatechin-3-gallate 
EGFR  Epidermal growth factor receptor 
Egr-1  Early growth response-1 
ER   Endoplasmic reticulum 
ErbB-2  Erythroblastic leukemia viral oncogene homolog 2 
Erk1/2  Extracellular signal-regulated kinase ½ 
EZH2  Enhancer of zeste homolog 2 
FACS  Fluorescent activated cell sorter 
FAS  Fatty acid synthase 
FDA  Food and Drug administration (United States) 
FOXO1  Forkhead box protein O1 
GGTP  γ-Glutamyltranspeptidase 
GSK3β  Glycogen synthase kinase 3β 
HER2  Human epidermal growth factor receptor 2 
HIF-1  Hypoxia-inducible factor-1 
IGF-1R  Insulin-like growth factor 1 receptor 
IL-8  Interleukin-8 
IκBα Inhibitor of nuclear factor of kappa light polypeptide gene enhancer 
in B-cells-α 
JMJD2A  Jumoji domain containing 2A 
JNK  c-Jun N-terminal kinase 
KDM4C  Lysine (K)-specific demethylase 4C 
MAPK  Mitogen-activated protein kinase 
Maspin  Mammary serine protease inhibitor 
MDR  Multidrug resistance 
MEF  Mouse embryonic fibroblast 
MMP  Matrix metalloproteinase 
MMR  Mismatch repair 
mRNA  Messenger RNA 
MRP-1  Multidrug resistance-associated protein-1 
MTT 3-[4,5-Dimethyl-2-thiazolyl]-2,5 diphenyltetrazolium bromide 
NAFLD  Non-alcoholic fatty liver disease 
NAT  N-acetyltransferase 
NF-κB  Nuclear factor-κB 
NSCLC  Non-small cell lung cancer 
NTR  Neurotensin receptor 
PAK1  Serine/threonine p21-activated kinase 1 
PARP  Poly ADP ribose polymerase 
p-EGFR  Phosphorylated epidermal growth factor receptor 
p-Erk1/2  phosphorylated Extracellular signal related kinase ½ 
P-gp  P-glycoprotein 
PKB  Protein kinase B (also known as Akt) 
PP2A  Phosphatases 2A 
PP5   Phosphatases 5 
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PPARα  Peroxisome proliferator-activated receptor-α 
PRP4B  Pre-mRNA processing factor 4B 
PTPN1  Protein tyrosine phosphatase, non-receptor type 1 
Rac1  Ras-related C3 botulinum toxin substrate 1 
RNAi  RNA interference 
ROS  Reactive oxygen species 
RT-PCR  Reverse transcription polymerase chain reaction 
SCLC  Small cell lung cancer 
siRNA  small interfering RNA 
Smac  Second mitochondria-derived activator of caspase 
SREBP-1c  Sterol regulatory element binding proteins-1c 
STAT3  Signal transducer and activator of transcription 3 
T790M T790M mutation results in an amino acid substitution at position 
790 in EGFR, from a threonine (T) to a methionine (M) 
TGF β1  Transforming growth factor β1 
TLR-4  Toll-like receptor-4 
TNBC  Triple-negative breast cancer 
TNF-α  Tumor necrosis factor-α 
TOP2A  DNAtopoisomerase II alpha 
TPA  12-O-tetradecanoylphorbol-13-acetate 
VEGF  Vascular endothelial growth factor 
VM   Vasculogenic mimicry 
WHO  World Health Organization 





Natural products are intimate part of human civilization. It is impossible to say exactly 
when menfolk started to take plant portions to cure various diseases. Medicinal plants have 
been employed for thousands of years as remedies for human ailments because of the 
presence of particular phytochemicals. Phytochemicals are the broad spectrum of compounds 
derived from plants (―phyto‖ means plant in Greek). In practice, the term ―phytochemicals‖ 
refers to a wide variety of compounds found in plants, but is mainly used to describe those 
plant natural products that may affect human/animal health, either in positive (as medicine) or 
negative (as narcotic/poison) manner. One of the important classes of phytochemicals consists 
of nutraceuticals. The term ―nutraceutical‖ was formed by the portmanteau of two different 
words: nutrition and pharmaceutical. DeFelice (1989) defined [1] nutraceutical as ―any 
substance that is a food or a parts of food, that provides medical or health benefits, including 
the prevention and treatment of disease‖. Later, the definition was modified by Health Canada 
and accordingly [2] nutraceutical is ―a product isolated or purified from foods that is 
generally sold in medicinal forms not usually associated with food. A nutraceutical is 
demonstrated to have a physiological benefit or provide protection against chronic disease‖. 
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Polyphenols are a fundamental class of nutraceuticals which are widely used as 
chemotherapeutic, chemoprotective as well as chemopreventive agents. Polyphenols are 
important constituents of many fruits, vegetables and cooking spices. 
Beverages like coffee, green and black tea, red wine, chocolate, nuts etcetera are good 
source of polyphenols. It has been found that many polyphenols are strong antioxidant, anti-
inflammatory, cardioprotective, hepatoprotective and neuroprotective agents as well as 
immune regulators, either by itself on in combination with others [3]. Curcuminoids are a key 
category of polyphenols. 
 
 
2. Origin and Historical Background 
 
Curcumin (diferuloylmethane), the major constituent of curcuminoids, is present in 
turmeric which is the dried powered rhizomes (underground stems) of Curcuma longa Linn 
of the Zingiberaceae family. The medicinal use of turmeric (haridra) was indicated in 
Sushruta Samhita, one of the three fundamental texts of Ayurveda (Indian traditional 
medicine) in the 6
th
 century BCE. Its medicinal uses were also found in Charaka Samhita 
(300-500 BCE). As Indian traditional medicine (Ayurveda) turmeric has been using to treat a 
broad range of common disorders for over 6000 years [4]. 
In India, turmeric is used as a cooking spice to induce nice yellow-orange color and 
flavor in curries, pickles and chutneys. It is used worldwide as a color inducing agent as well 
as preservative in American mustard, mayonnaise, butter and margarine and has been 
designated as international food additive E100 [5]. Turmeric is in the GRAS (Generally 
Recognized As Safe) list of the US Food and Drug Administration having GRN number 460 
[6]. This royal spice was introduced to the western world in the 13
th
 century by Marco Polo, 
one of the early European explorers to the Indian subcontinent [7, 10]. Since then India is the 
highest turmeric producing country in the world [8-10]. Turmeric has at least 76 synonyms 
listed in the 1999 World Health Organization (WHO) monograph [11]. A few popular names 
are Haridra (Sanskrit), Halood (Bengali), Haldi (Hindi), Kurkum uqdah safra (Arabic), Ukon 
(Japanese), Chiang Huang (Chinese), Ulgeum (Korean), Kurkuma (German), Safran des 
Indes (French), kurkumy (Russian), Indian saffron etc. 
Besides its culinary appeal turmeric has a glorious history of uses as a therapeutic and 
preventive agent against a wide array of disorders and diseases, either by itself or in 
combination with other agents. As an ancient household remedy a hot poultice of turmeric 
powder and slaked lime (chun-halood in Bengali) is applied locally to relieve muscular pain 
and inflammation caused by sprain and injury. 
In some parts of India, a drink made from fresh turmeric, ginger roots and honey in a 
glass of hot milk are given to women twice daily after childbirth. 
A poultice of fresh turmeric paste is also applied to the perineum as wound healing for 
lacerations in the birth canal [12]. Its traditional uses as strong therapeutic or preventive agent 
against several human diseases include, but are not limited to, diabetes, fibrosis, asthma, 
rheumatism, allergies, inflammation, intestinal worms, atherosclerosis, diarrhea, dyspepsia, 
intermittent fevers, biliousness, cough, sinusitis, constipation, jaundice, urinary discharges, 
flatulence, leukoderma, amenorrhoea, acne, colic inflammation, respiratory ailments, lupus 
nephritis, irritable bowel syndrome, menstrual difficulties, anorexia, coryza, hematuria, 
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hemorrhage, neurodegenerative, Alzheimer‘s disease, and cancer [9, 12-16]. The presence of 
turmeric is essential in most of the religious ceremonies in Hinduism. 
The sequence of curcumin in natural product chemistry can be accessed as: 
 
Natural products → Plant natural products → Phytochemicals → Nutraceuticals → 
Polyphenols → Curcuminoids → Curcumin 
 
In the same way the categorization of Curcuma longa Linn is shown in Table 1. 
Depending upon the soil composition and geographical diversity, the chemical 
composition of turmeric varies to some extent. 
 









Species: C. longa 
Scientific Name: Curcuma longa 
 
The presence of about 235 compounds of which 109 sesquiterpenes, 68 monoterpenes, 22 
diarylheptanoids and diarylpentanoids, 8 phenylpropene and other phenolic compounds, 5 
diterpenes, 4 sterols, 3 triterpenoids, 2 alkaloids and 14 other compounds have been identified 
in turmeric. Among the diarylheptanoids three compounds are curcuminoids, the major 
pharmacologically active ingredients of turmeric. Curcumin, the major curcuminoid which 
constitutes 3-5% of turmeric has been consumed for medicinal purposes for thousands of 
years [14, 17]. Two other curcuminoids are demethoxycurcumin and bis-demethoxycurcumin 
(Figure 1). Commercial curcumin is a mixture of three curcuminoids: curcumin (71.5%), 
demethoxycurcumin (19.4%) and bis-demethoxycurcumin (9.1%) [14]. 
The isolation of curcumin, the principal constituent of turmeric responsible for its vibrant 
yellow-orange color, first reported by Vogel and Pelletier [18] in 1815 from the plant 
Curcuma longa as ―yellow coloring-matter‖ and named as ―curcumin‖. Later, it was found to 
be a mixture of resin and turmeric oil [19]. Curcumin was isolated in 1842 but the chemical 
formula was not reported [19, 20]. The chemical structure of curcumin as diferuloylmethane 
was identified by Milobedzka et al. in 1910 and the first synthesis of curcumin was reported 
from the same laboratory in 1913 [19, 21, 22]. The chemical structure of curcumin was 
confirmed in 1973 [23] and a few years ago in 2007, its solution structure was reported [24]. 
There are at least 125 plants under the genus Curcuma but curcuminoids have been 
identified only from 7 Curcuma plants [3, 10, 25, 26] till date. 
As mentioned earlier, Curcuma longa Linn is the major source (3-5% curcuminoids) of 
curcuminoids and curcumin. Curcuminoids are also reported from C. phaeocaulis (1-3% 
curcuminoids), C. xanthorrhiza (1-2% curcuminoids), C. zedoaria (~ 0.1% curcuminoids), C. 
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aromatic (< 0.1% curcuminoids), C. comosa (< 0.1% curcuminoids), and C. mangga (< 0.1% 
curcuminoids). Curcuminoids have also been identified in other genera like Costus speciosus, 
Etlingera elatior, Zingiber cassumunar etc. 
Besides the ancient literature, the first scientific report related to the medicinal uses of 
Curcuma was published in 1748 [27, 28]. After 67 years a review detailing the biological and 
medicinal properties of turmeric (curcumin) was published [18]. In 1937, Oppenheimer 
reported the medicinal activity of turmeric against biliary diseases [29]. 
In 1949, Schraufstatter and Bernt reported [30] the antibacterial activity of curcumin and 
its pharmacological activity to cure eye disease was reported [31] by Chaudhri in the 
following year. Jiang and co-workers evaluated the anticancer activity of four natural 
products viz. camptothecin, harringtonin, cantharidin and curcumin on human tumor biopsies 
in an in vitro soft agar clonogenic assay system and reported their findings in 1983 [32]. 
 
 
Figure 1. Structure of Curcuminoids. 







1801-1900 17 0 
1901-1950 92 1 
1951-1980 373 6 
1981-1990 264 5 
1991-2000 1101 75 
2001-2010 7073 2505 
2011 1576 1282 
2012 1948 1637 
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They reported curcumin as ―relatively ineffective‖ antitumor agent than camptothecin, 
and harringtonin. Probably this was the first evaluation of curcumin against cancer. Kuttan 
and colleagues published the anticancer activity of curcumin in 1985 [33]. 
The acceptance of traditional medicine is considered as an alternative form of modern 
health care system. Over the past quarter century there has been growing interest in a possible 
role of curcumin on various diseases. The research topic ―curcumin‖ in any chemistry/health 
related search engine hits a huge number of results, including research articles, reviews, 
communications, patents, books, editorials etc. Comparative results obtained up to December 
31, 2013 from the two major chemistry and health related databases viz. SciFinder Scholar 
and PubMed Central are presented in Table 2 and Figure 2. After publication of the initial 
studies on curcumin as a promising anticancer agent in the mid-eighties [32, 33], scientists 
from all over the world paid their attention to this novel nutraceutical. It is now established 
that cancer is neither a single disease nor a comparatively new disease. 
 
 
Figure 2. Growing interest (comparative statistics) on Curcumin research. 
 
3. Curcumin and Cancer 
 
It is well-known that cancer is a leading cause of death worldwide and accounted for 8.2 
million deaths in 2012 among which 70% occur in low and middle income countries. 
According to the World Health Organization the annual cancer cases will rise from 14 million 
in 2012 to 22 within the next two decades [34, 35]. 
On the other hand, cancer is a group of more than 200 neoplastic diseases caused by the 
dysregulation of multiple factors [36]. Therefore, there is a continuous need to introduce new 
anticancer agents to reduce both cancer incidence and cancer-related mortalities. 
Moreover, cancer cells often adapt to develop resistance to chemotherapeutic agents, 
consequently a better understanding of anticancer agents induce or inhibit carcinogenesis 
could lower tumor incidence or provide help to manage this disease effectively. Current 
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research in this field directs to develop novel chemotherapeutic agents, which are more potent 
tumor-selective cytotoxic agents and can circumvent drug resistant cancer cells. A tentative 
estimation states that about 25% drugs are still derived from the Mother Nature and 74-80% 
of all cancer drugs have their origins in natural products i.e. these drugs are modified natural 
products [37, 38]. 
Several scientists around the world are actively engaged to investigate the anticancer 
activity of the ancient natural product curcumin. Consequently a huge number of publications 
detailing its anticancer activity have been published. A concise discussion regarding the 
effects of curcumin on five leading cancers with respect to cancer mortality viz. lung, liver, 
stomach, colorectal and breast (Figure 3) can be found in the sequel. The outcome of some 
important and comparatively recent studies have been summarized in this chapter. 
 
 
3.1. Lung Cancer 
 
The overall percentages of occupancy (13.0) and mortality (19.4) of lung cancer were 
highest worldwide among all cancers in 2012 [34, 35, 39]. About 85-90% lung cancers are 
non-small cell lung carcinoma (NSCLC) and 5-year prevalence is only 5.8%. The 
chemotherapeutic and chemopreventive activities of curcumin against lung cancer have been 
reported. Singh and co-workers reported [40] that Curcumin can behave as a potential 
adjuvant chemotherapeutic agent against NSCLC by enhancing chemotherapeutic effect of 
the drug Vinorelbine (trade name Navelbine) in H520 cells in vitro. Independent treatment of 
Cucumin and Vinorelbine induced 23.7% and 38% apoptosis respectively whereas 
pretreatment with Curcumin amplified Vinorelbine induced apoptosis to 61.3%. 
The mechanism of action suggested that Curcumin triggered apoptosis by enhancing the 
protein expression of Bax and Bcl-Xs while the protein expression of Bcl-2 and Bcl-XL was 
reduced. Consequently, release of apoptogenic Cytochrome c took place, and the activity of 
Caspase-9 and Caspase-3 boosted. Here it is important to mention that Bcl-XL is a protein 
consisted by 233-amino acids associated with antiapoptotic properties. 
On the other hand, one of the alternatively spliced transcripts of the Bcl-x gene codes for 
the protein Bcl-xS, which lacks 63 amino acids present in Bcl-xL and associated with 
proapoptotic activity. Lev-Ari et al. exposed the non-small cell lung cancer PC-14 cells for 
72h to curcumin (0-50 μM) and apoptosis was determined by FACS analysis. Finally, the 
COX-2, EGFR, ErbB-2 and p-Erk1/2 expressions were measured by Western blot analysis. 
The results showed that inhibitory effect of Curcumin on survival and apoptosis of lung 
cancer cell lines was significantly higher in the COX-2-expressing cells than in the COX-2-
deficient cells. Curcumin decreased COX-2, EGFR and p-Erk1/2 expressions in a dose-
dependent manner [41]. Radhakrishna-Pillai et al. demonstrated Curcumin-induced apoptosis 
in two human lung cancer cell lines A549 (adenocarcinomic human alveolar basal epithelial 
cells) and H-1299 (also known as NCI-H1299 or CRL-5803). 
Upon Curcumin treatment the growth of both the cell lines was inhibited in time and 
concentration dependent manner [42]. In the presence of 40 mM curcumin a decrease in 
expression of p53, bcl-2, and bcl-XL was observed after 12 h exposure while Bak and Caspase 
genes remained unchanged up to 60 mM curcumin but showed decrease in expression levels 
at 80 – 160 mM. It was suggested that the apoptotic cell death by curcumin involves multiple 
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pathways. Curcumin up-regulates various pro-apoptotic genes and simultaneously down-
regulate some of the anti-apoptotic genes. Homo-dimerization or hetero-dimerization of these 
pro- and anti-apoptotic genes in favor of apoptosis was one of the suggested mechanisms of 
Curcumin-induced apoptosis. The mechanistic pathway by which Bax and Bak, two 
multidomain pro-apoptotic Bcl-2 family members, regulate curcumin-induced apoptosis was 
revealed by Shankar et al. [43]. The study involved the use of mouse embryonic fibroblasts 
(MEFs) deficient in Bax, Bak or both genes. The treatment with Curcumin caused an 




All cancers excluding non-melanoma skin cancer. Specific type of cancer and its percentage of 
contribution toward cancer related mortality in 2012 can be shortened [39] as: Lip, oral cavity 
(1.8), Nasopharynx (0.6), Other pharynx (1.2), Gallbladder (1.7), Pancreas (4.1), Larynx (1.1), 
Melanoma of skin (0.7), Kaposi sarcoma (0.3), Corpus uteri (0.9), Ovary (1.9), Testis (0.1), 
Kidney (1.7), Brain, nervous system (2.3), Thyroid (0.5), Hodgkin lymphoma (0.3), Non-Hodgkin 
lymphoma (2.4), Multiple myeloma (1.0), Leukaemia (3.2). 
Figure 3. Mortality due to Cancer in 2012 (worldwide). 
Consequently mitochondrial membrane potential dropped which favored the cytosolic 
release of apoptogenic molecules such as Cytochrome c and Smac/DIABLO from 
mitochondria to cytosol to activate caspase-9 and caspase-3 and eventually apoptosis. The 
authors also suggested that Curcumin-induced caspase activation might be amplified due to 
induction of Apaf-1 because it also caused an increase in the protein level of Apaf-1 in wild-
type MEFs. Taken together, both Bax and Bak are essential for curcumin-induced apoptosis, 
and over-expression of Smac/DIABLO as interventional approach to combat with Bax- 
and/or Bak-deficient chemoresistant cancers for curcumin-based therapy. 
Cisplatin (or cisplatinum, or cis-diamminedichloroplatinum[II]) has been using as a novel 
anticancer drug against several types of cancer for the past more than three decades  
(Figure 4, Synthesis: 1970; FDA approval: 1978). 
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However, the efficiency of Cisplatin-based chemotherapy can‘t reach to its expected 
level; because of de novo drug resistance in the advanced stage of cancer or in cancer cells 
acquiring cisplatin resistance during therapy. It has been found that the late detection and 
growing drug resistance are the two main causes of high mortality due to lung cancer [39]. 
Under this circumstances, the chemosensitization strategy might be beneficial to fight 
against lung cancer. As an excellent chemosensitizer, Curcumin can sensitize Cisplatin-
mediated apoptosis in human non-small cell lung cancer H460 cells. 
The mechanism involves the generation of superoxide anion and down-regulation of the 
anti-apoptotic Bcl-2 protein through proteasomal degradation and subsequent sensitization of 
the cancer cells to Cisplatin-assisted apoptosis. 
 
 
Figure 4. Example of drugs demonstrated synergistic effect with Curcumin. 
In a nutshell, treatment of the non-small cell lung cancer H460 cells with Cisplatin using 
Curcumin as chemosensitizer resulted in reversal of Bcl-2-facilitated cisplatin resistance and 
consequently increased apoptosis [44]. 
Not only as chemotherapeutic and/or chemosensitizing agent, Curcumin also 
demonstrated its chemopreventive activity immensely against lung cancer. It is known that 
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TNF-α and oxidants activate transcription factors such as NF-κB, which is involved in the 
transcription of proinflammatory mediators, including Interleukin 8 (IL-8). 
It was found [45] that the treatment of cultured alveolar epithelial cells (A549) with 
hydrogen peroxide (100 µM) and TNF-α (10 ng/ml) the NF-κB and activator protein-1  
(AP-1) activation were increased significantly and IL-8 was released. The treatment with 
Curcumin inhibited both hydrogen peroxide and TNF-α-mediated activation of NF-κB and 
AP-1; the release of IL-8 was inhibited also. 
Moreover, an increased level of glutathione and glutamylcysteine ligase catalytic subunit 
mRNA expression were observed in curcumin-treated A549 cells in comparison to untreated 
cells. 
The study suggested that curcumin contains multiple properties like (i) it can act as an 
oxygen radical scavenger, (ii) antioxidant through modulation of glutathione levels, and (iii) 
anti-inflammatory agent through inhibition of IL-8 release in lung cells. It is known that the 
drug Erlotinib (an EGFR-tyrosine kinase inhibitor, Figure 4) can produce satisfactory result in 
human lung adenocarcinoma PC-9 cells by inducing apoptosis. However Erlotinib exhibited 
weaker effect on Erlotinib-resistant H1975 (or NCI-H1975) and H1650 (NCI-H1650) human 
lung cancer cells than Curcumin pretreated Cisplatin. The combination of Curcumin and 
Erlotinib showed similar effects on apoptosis as the combination of Curcumin and Cisplatin 
in Erlotinib-resistant non-small cell lung cancer cell lines. In addition, this combination 
(Curcumin and Erlotinib) significantly increased the cytotoxicity of Erlotinib to Erlotinib-
resistant NSCLC cells and reduced the tumor growth in xenograft mouse model.  
The mechanism of action involves the down-regulation of the expressions of EGFR, p-EGFR, 
and survivin, and inhibition of the NF-κB activation by sustaining IκB expression level in 
Erlotinib-resistant NCI-H1650 and NCI-H1975 cells [46]. The primary reason of Erlotinib-
resistance in lung cancer includes T790M mutant EGFR receptor and c-Met gene 
amplification. It has been found [47] that coadministration of Curcumin and Erlotinib in PC-9 
lung cancer cells accelerated apoptosis by elevation of IκB expression. Also the 
coadministration of Curcumin and Erlotinib to siRNA-pretreated PC-9 lung cancer cells 
significantly increased the cytotoxicity by reducing the cell viability because of synergistic 
effect. This combination remarkably reduced the tumor growth in mice. The efficacy of 
Curcumin on the growth and metastasis of H1975 (NSCLC) in an intralung tumor mouse 
model has been reported [48] using ectopic and orthotopic lung tumor mouse models.  
The control group was given AIN-076 control diet whereas the investigating group received 
same food in addition to 0.6% curcumin 14 days prior to cell implantation and until the end of 
the experiment. The orthotopic tumor was generated by percutaneous injection of the lung 
cancer cells in Matrigel into the left lung of CD-1 nude mice. The successive Western blot 
analysis exhibited that the expressions of IkB, nuclear p65, COX-2 and p-ERK1/2 were 
down-regulated by curcumin in vitro. A 36% decrease in weight of intralung tumors of 
orthotopic human NSCLC xenografts with sufficient increase in survival rate of the 
investigating group was observed. Cigarette smoke is considered as one of the main reasons 
of lung carcinogenesis. The presence of carcinogens such as Benzo[a]pyrene, the free radicals 
like hydroxyl radicals, superoxide radicals have the required potential to activate NF-κB 
which can inhibit apoptosis, stimulate proliferation and mediate tumorigenesis. Accordingly 
NF-κB is an ideal target for preventing cigarette smoke-mediated lung carcinogenesis.  
The effect of Curcumin on cigarette smoke-induced NF-κB activation and NF-κB-regulated 
gene expression was studied in H1299 (human non-small cell lung carcinoma), A549 (human 
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lung epithelial cell carcinoma), and BEAS-2B (immortalized human bronchial epithelial) 
cells [49]. The results showed that pre-treatment with curcumin stopped the cigarette smoke-
prompted DNA-binding of NF-κB and NF-κB-dependent reporter gene expression. 
Tissue invasion and metastasis are considered as one of the hallmarks in cancer. It has 
been found that relapse and/or metastasis are very common for lung cancer patients after 
complete excision of the cancer, even if they were at stage IA [50]. The protein Rac1 is 
widely related in cytoskeleton rearrangements (occur in physiological events such as cell 
movement. Cytoskeletal defects are frequently associated with cancer metastasis.) and 
migration, invasion as well as metastasis of cancer cells. Curcumin inhibits EGF or TGF β1-
induced 801D lung cancer cell migration and invasion [51]. 
The decrease in the metastasis in curcumin-treated cells was anticipated due to the 
inhibition of Rac1/PAK1 pathway signaling and the decreased MMP-2 and MMP-9 
expression. The anti-invasion activity of curcumin was confirmed by the relation between 
Rac1 and the growth and metastasis inhibitory effect of curcumin in vivo by the xenograft 
model. In another investigation [52] the growth inhibitory effect of Curcumin in both the non-
small cell lung cancer (A549) and small cell lung cancer (SCLC) H460 (human) cell lines 
have been reported. The study suggested that Curcumin can prevent cell proliferation by the 
upregulation of CDK inhibitors, p27 and p21, and downregulation of Cyclin D1 although the 
compound precludes progression and metastasis through induction of FOXO1. 
An interesting synergism of Curcumin with another important phytochemical Resveratrol 
(trans-3,5,4'-Trihydroxystilbene, Figure 4) against lung carcinogenesis has also been reported 
[53]. The Benzo[a]pyrene treatment in mice resulted in a substantial increase in the protein 
expression of phosphorylated p53 [specifically at ser15] which confirmed p53 hyper-
phosphorylation while enzyme activities of caspase 3 and caspase 9 were observed to be 
potentially reduced. The combined treatment of Curcumin and Resveratrol to benzo[a]pyrene 
treated mice resulted in a significant decrease in p53 hyper-phosphorylation as well as 
regulation of cellular metabolism enzymes and caspases. 
 
 
3.2. Liver Cancer 
 
Liver cancer was the second leading cause of cancer related deaths (9.1%) worldwide in 
2012 which accounted only 1.9% five-year prevalence [39]. In general, hepatocellular 
carcinoma is resistant to standard chemotherapy. Surgery or liver transplantation at the early 
stage may provide longer survival to the patients. However, about 80% of liver cancer 
patients with advanced stage are not amenable to liver transplantation or surgery and this is 
the main reason of poor prognosis in liver cancer [54]. Hence it is highly challenging to 
identify/develop effective drug to combat liver cancer. Curcumin demonstrated its 
antiproliferative activity against human HCC (hepatocellular carcinoma) cells by arresting the 
cell cycle in G2 and regulating Wnt signaling pathway [55]. The proliferation is inhibited by 
apoptosis in a dose-dependent manner. The interruption of Wnt signaling takes place by 
reduction of β-catenin activity, which in other word suppresses the expression of β-catenin 
target genes (VEGF, Cyclin D1 and c-myc). The Wnt signaling pathway is considered as an 
important factor for the development, growth, survival, proliferation and metastasis of the 
cancer cells. The GSK3β and β-catenin play the major role in this pathway and therefore, a 
few factors associated with this pathway are considered as potential targets for anticancer 
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therapy. Curcumin demonstrated the anti-migratory activity by suppressing the TPA-induced 
activation of the Wnt signaling and the related cell migration in Hep3B liver cancer cells [56] 
in vitro and tumor growth in vivo. 
The molecular mechanism of Curcumin-induced apoptosis in human liver cancer (Huh7) 
cells was studied [57]. It is known that Fas ligand (FasL or CD95L) is a type-II 
transmembrane protein that belongs to TNF (tumor necrosis factor) family. Upon Curcumin 
treatment of Huh7 cells significant increase in Fas and FasL, caspase-3 activation as well as 
PARP cleavage have been observed. Rapid activation of p-38 under the influence of 
Curcumin triggers apoptosis via p-38-dependent up-regulation of FasL. High expression of 
FAS is associated with many types of cancer including liver cancer. 
It has been found that Curcumin can down-regulate FAS expression to inhibit its 
intracellular activity and mRNA level in a concentration-dependent manner in HepG2 liver 
cancer cells in vitro. Curcumin induced apoptosis in HepG2 liver cancer cells with the IC50 
value of 8.84 μg/mL determined by MTT assay. Not only FAS, the siRNA also showed similar 
result with Curcumin [58]. From flowcytometric analysis it was concluded that up-regulation of 
the expression of tubulin occurred by the treatment with Curcumin in HepG2 liver cancer 
cells. Treatment with Curcumin caused cell-cycle arrest at G2/M phase with concomitant 
losses from G0/G1 phase in a concentration-dependent manner. 
The AFM imaging demonstrated that the membrane toxicity and cytoskeleton destruction 
may be the therapeutic targets of Curcumin [59]. 
It has been cited in many literatures that during oxidative stress the expression of TLR-4 
is regulated. Excessive intracellular ROS production up-regulates TLR-4/2 expression 
whereas elimination of ROS by specific scavengers inhibits the up-regulation of TLR-4 
expression and suppresses transcription of TLR-4 mediated genes. Therefore it is considered 
that ROS triggers the TLR-4 signaling pathway [60]. On the other hand, Myd-88 is a down-
stream adaptor molecule of TLR-4 to conduct signals to begin translocation of NF-κB and 
activation of MAPKs which ultimately leads to cell death via apoptosis. The initiator of the 
caspase cascade, caspase-8, is activated by cleavage through the interaction with Fas-linked 
death domain via Myd-88. The executor of apoptosis in caspase cascade, caspase-3, can also 
be activated by cleavage after the activation of caspase-8 [61]. Curcumin-induced inhibition 
of cell proliferation as well as cell death through apoptosis in MHCC97H human liver cancer 
cell lines followed the sequence: activation of ROS → TLR4/Myd-88 → activation of 
Caspase-3/Caspase-8 [62]. The apoptosis occurred in a dose-dependent manner through 
activating intracellular ROS generation. The augmented intracellular ROS formation 
stimulated the TLR-4/MyD-88 signaling pathway. 
Consequently the activation of caspase-8 and caspase-3 surfaced, which ultimately led to 
apoptosis in MHCC97H human liver cancer cells. 
Vasculogenic mimicry (VM) is considered as one of the major factors in cancer invasion 
and it denotes the process in which the cancer cells mimic endothelial cells by forming blood 
channels. The potential of Curcumin on vasculogenic mimicry of human liver 
adenocarcinoma cells (SK-Hep-1) has been studied in vitro. Curcumin inhibited vasculogenic 
mimicry, decreased cell migration and MMP9 (matrix metalloproteinase-9) production of the 
cancer cells. Curcumin exhibited the anti-VM efficacy by down-regulating the Akt (or PKB) 
and STAT3 signaling pathways [63]. 
Two-dimensional electrophoresis and mass spectral investigations were carried out to 
reveal the effect of Curcumin on the proteome of human liver cancer HepG2 cell lines [64]. 
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The HepG2 cells were treated with Curcumin (30 μmol/L) and the proteins were separated. 
An up-regulation of cyclin-dependent kinase inhibitor 2A, carnitine deficiency-associated 
gene, replication protein A2 and protein disulfide isomerase was noted whereas down-
regulation of Nm23 protein, Stathmin 1/oncoprotein 18, Ran binding protein 1, endoplasmic 
reticulum-60 protease and proliferating cell nuclear antigen were noted. The data indicated 
that Curcumin treatment might led to inhibit tumor growth, promote apoptosis by arresting 
cell cycle, and prevent tumor invasion as well as metastasis. 
The anti-atherosclerosis and hypolipidemic efficiencies of Curcumin might correlate with 
promotion of the transmembrane transport of fatty acids and maintain the stability of the cell 
membrane. 
Hypoxia of solid tumor is one of the major problems to treat cancer. This situation arises 
when the cells are deprived of required oxygen. As a tumor develops, it promptly outgrows its 
blood supply, leaving portions of the tumor with areas where the oxygen concentration is 
significantly lower than in healthy tissues. Hypoxic microenvironements in solid tumors are 
in result of available oxygen being consumed within 70 to 150 μm of tumor vasculature by 
fast growing tumor cells thus limiting the amount of oxygen available to diffuse further into 
the tumor tissue. To support continuous growth and cell proliferation in hypoxic 
environments, cancer cells are found to alter their metabolism. Hypoxia-inducible factor-1 
(HIF-1) plays a key role in cellular responses to hypoxia counting the transcriptional 
activation of a number of genes those are involved in tumor angiogenesis [65]. HIF-1 is 
composed of HIF-1a and aryl hydrocarbon receptor nuclear trans-locator (ARNT). It was 
reported that between these two subunits of HIF-1; ARNT was found to be attacked by 
curcumin in several cancer cell types, including mice bearing Hep3B liver cancer cell lines 
and in xenografted tumors. Curcumin activated the proteasomal degradation of ARNT 
through oxidation and ubiquitination processes to suppress ARNT, erythropoietin, and VEGF 
(a major HIF-1 target angiogenic factor) leading to overall down-regulation of HIF-1 in 
tumors [66]. In brief, the study showed that the anticancer effect of Curcumin in tumor 
hypoxia was because of ARNT degradation which caused HIF-1 inactivation. In the case of 
human liver cancer (HepG2) cells in vitro Curcumin treatment significantly reduced the 
hypoxia-mediated HIF-1 protein level by repressing the expression of VEGF in vascular 
endothelial cells which eventually inactivated the transcriptional activity of HIF-1 under 
hypoxia. Consequently, curcumin efficiently blocked the hypoxia-stimulated angiogenesis of 
vascular endothelial cells. These findings supported that Curcumin might play major roles in 
tumor suppression through the inhibition of HIF-1-mediated angiogenesis [66]. 
It has been stated earlier that the invasion of cancer cells is considered as an important 
and distinctive step toward metastasis. The blockage of this physiological incident by 
medicines or supplements/nutraceuticals prolongs the life span of an affected host. Kozuki et 
al. suggested [67] that antioxidative property of Curcumin might be involved in its anti-
invasive effect. The authors evaluated the efficacy of Curcumin on the proliferation and 
invasion of the rat ascites hepatoma AH109A cells in vitro and ex vivo. To satisfy this goal, a 
co-culture system of the hepatoma cells with mesothelial cells derived from rat mesentery 
was subjected for invasion study. Curcumin reduced the hepatoma slipping motility in a 
concentration-dependent manner up to 5 µM and afterward maintained the effect up to 20 µM 
with a minimum impact on cell proliferation. 
Interestingly, the sera isolated from rats, those consumed Curcumin orally, also inhibited 
the AH109A cellular invasion when added to the culture medium. Curcumin and curcumin-
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containing rat sera inhibited the ROS-potentiated invasive capacity by concurrently treating 
AH109A cells with hypoxanthine, xanthine oxidase and either of Curcumin samples. 
Curcumin demonstrated synergism with other anticancer agents against a number of 
cancers including liver cancer. Curcumin along with EGCG (a natural polyphenol, mainly 
present in green tea, white tea and in black tea with low abundance, Figure 3) exhibited 
inhibition against acrylamide (a proven rodent carcinogen)-induced human liver cancer 
HepG2 cell proliferation. Acrylamide (≤100 μM) induced CYP2E1 expression potentially and 
knockdown of CYP2E1 restrained acrylamide to increase viability of HepG2 cells [68]. 
Moreover, acrylamide up-regulated EGFR, Cyclin D1 and NF-κB, which contributed to cell 
proliferation. 
Curcumin and EGCG successfully down-regulated the protein expression of CYP2E1, 
EGFR, Cyclin D1 and NF-κB signaling pathway. Accordingly subsequent inhibition of 
acrylamide-induced HepG2 cell proliferation was observed. Prevention of angiogenesis 
signifies a fascinating approach to hepatocellular carcinoma as it is one of the hypervascular 
solid tumors. Curcumin demonstrated synergistic effect in combination with two other drugs 
namely: leflunomide (an antirheumatic drug) and perindopril, an angiotensin converting 
enzyme inhibitor (ACEI), against DEN-induced hepatocellular carcinoma in mice [69]. DEN 
was administered to the mice for a period of eight weeks and a notable increase in 
immunohistochemical staining of CD31-positive endothelial cells and consequently hepatic 
microvessel density (MVD) was observed as compared to normal liver. Following the trend, 
up-regulation of HIF-1α and VEGF was noticed in the DEN-treated mice in comparison to 
their normal counterpart. Monotherapy with leflunomide and perindopril showed week 
inhibition whereas Curcumin demonstrated down-regulation of HIF-1α. 
The combined therapy of these three agents (Curcumin, leflunomide and perindopril) 
resulted synergism through suppression of VEGF expression and exhibiting inhibitory action 
on neovascularization and subsequent inhibition of angiogenesis. Nowadays it is well-known 
that metastasis of liver is a major cause of mortality in colorectal cancer (CRC). Curcumin in 
combination with ulinastatin (a glycoprotein which acts as urinary trypsin inhibitor) inhibited 
CRC liver metastases in human colorectal cancer cell lines HCT-116 in vitro through 
modulation of MMP-9 and expression of E-cadherin. Because of the synergistic role of 
Curcumin along with ulinastatin (Figure 3) the inhibition of HCT-116 cell migration and 
invasion occurred [70]. The synergism of Curcumin and ulinastatin was also evaluated in 
mouse model through dynamically tracking the development of tumor and its therapeutic 
responses by bioluminescence imaging. A prolonged survival of tumor-bearing mice those 
treated with the combined agents (Curcumin and ulinastatin) was noticed. 
Besides the above, Curcumin confirmed its activity to prevent the undesirable fat 
accumulation in human hepatocarcinoma cells [71]. It is known that NAFLD (Non-alcoholic 
fatty liver disease) is one of the major metabolic syndromes globally, caused by the 
accumulation of liver triglycerides (TG). The underlying reason of NAFLD is an imbalance 
between uptake, synthesis, export, and oxidation of fatty acids. Curcumin demonstrated 
hypolipidemic effect by suppressing lipid accumulation and TG as well as total cholesterol 
(TC) levels in oleic acid-induced human HepG2 liver cancer cells. In the first stage, 
Curcumin enhanced AMPK phosphorylation to stop the anabolism and promote catabolic 
pathway by up-regulating PPARα and down-regulating the activity SREBP-1c and FAS to 
reduce hepatic lipogenesis. 
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Because of low bioavailability and half-life, a small portion of the orally administered 
Curcumin can reach at the site of action. Therefore, Curcumin metabolites have been assumed 
to be responsible for its bioactivity. Curcumin glucuronide (Figure 5) was reported as the 
major metabolite present in the plasma after oral administration of Curcumin in rats [72]. 
An interesting study was carried out by Nakagawa and co-workers to compare the 
activity of Curcumin and its major metabolite Curcumin glucuronide (synthetic) on gene 
expression in HepG2 human liver cancer cell lines in vitro. The RT-PCR (Reverse 
transcription polymerase chain reaction) was used to detect the RNA expression levels. The 
effect of Curcumin and Curcumin glucuronide on mRNA expression of ACOX1, GSTT1, 
CAT, and AREG genes was studied. IL-8 expression was also evaluated by real time RT-PCR, 
because Curcumin inhibits IL-8 production. 
 
 
Figure 5. Curcumin glucuronide: the major metabolite of Curcumin. 
The results showed that the expression of all the tested genes (ACOX1, GSTT1, CAT, 
AREG, and IL-8) was significantly decreased by Curcumin treatment, whereas the effect of 
Curcumin glucuronide was found to be very low. 
Curcumin glucuronide down-regulated the expression of GSTT1 to some extent only. In 
brief, the in vitro cell culture study suggested that Curcumin per se was highly active, rather 
than its major metabolite Curcumin glucuronide. 
 
 
3.3. Stomach Cancer 
 
Stomach cancer remains one of the major health issues globally. It is the third leading 
cause of cancer death worldwide with a five-years prevalent of 4.7% in 2012. Anticancer 
activity of Curcumin on various stomach cancer cells was investigated. It successfully 
inhibited the cell proliferation of BGC-823 (human stomach adenocarcinoma), MKN-45 
(human gastric adenocarcinoma) and SCG-7901 (human gastric cancer) cell lines in a 
concentration- (1, 5, 10 and 30 μM) and time- (24, 48, 72 and 96 h) dependent manner by 
inducing apoptosis [73]. Annexin A5 affinity assay (a test to quantify the number of cells 
Complimentary Contributor Copy
Debasish Bandyopadhyay 18 
undergo apoptosis; the assay uses the protein annexin A5 to tag apoptotic and dead cells, and 
the numbers are then counted using either flow cytometry or by a fluorescense microscope) 
confirmed that apoptosis occurred at the dose of 10 and 30 μM when the cells were treated for 
24 and 48 h. Total protein analysis revealed that Curcumin up-regulated 33 proteins and 
down-regulated 42 proteins as determined by spot densitometry. A total of 52 proteins with 
substantial Mascot scores (Mascot is a software search engine that uses mass spectrometry 
data to identify proteins from peptide sequence databases) were identified, those were 
associated with cancer development and progression. The siRNA targeting Chk1 (Checkpoint 
kinase 1) sensitized the SCG-7901 cells to undergo Curcumin-mediated apoptosis. In another 
study Curcumin inhibited the fore stomach carcinogenesis induced by benzo[a]pyrene [B(a)P] 
and micronuclei formation induced by cyclophosphamide in mice [74]. 
The therapeutic potential of chemotherapy to combat stomach cancer is limited because 
of chemoresistance which is associated with the expression of NF-κB. Etoposide and 
doxorubicin are two well-studied anticancer agents with ability to suppress the growth of 
human gastric cancer SGC-7901 cells in a time- and concentration-dependent manner. The 
drug synergy of Curcumin in combination with etoposide (Figure 4) or doxorubicin (Figure 4) 
was studied [75]. Application of Curcumin in addition to etoposide or doxorubicin suppressed 
the proliferation of SGC-7901 human gastric cancer cell lines. Inhibitory rate was found to 
be: etoposide vs. (etoposide + curcumin), 35% vs. 48%, p<0.05 and doxorubicin vs. 
(doxorubicin + curcumin) 33% vs. 45%, p<0.05. The results showed that Curcumin 
intensified the antitumor effects of etoposide and doxorubicin by inhibiting the up-regulation 
of NF-κB and NF-κB-regulated anti-apoptotic downstream targets Bcl-2 and Bcl- XL. The 
combination of Curcumin and the anticancer agents (etoposide or doxorubicin) showed 
substantial possibility to become an effective therapy for gastric cancer that could synergize 
the effect of chemotherapeutics and overcome chemoresistance. 
The anticancer effect of Curcumin on human gastric carcinoma (AGS), normal gastric 
epithelial cell line (GES-1) and human gastric cancer cell (MGC-803) was studied. It was 
found that Curcumin induced apoptosis in the cancer cells and the cytotoxicity was selective 
toward cancer cells in comparison to normal cells. The molecular mechanism was 
investigated in human gastric carcinoma (AGS) cell lines. An increased externalization of 
phosphatidylserine residue was observed by Annexin 5/PI staining along with amended 
cleavage of procaspase-3, -7, -8 and -9. The study revealed [76] that apoptosis was led by 
curcumin mediated ER stress and mitochondrial dysfunction as evidenced by expression of 
CHOP protein, phosphorylation of JNK and repression of SERCA2ATPase, discharge of 
Cytochrome c, reduction of Bcl-2 and fall of mitochondrial membrane potential. Notably, 
curcumin reduced cytosolic and ER Ca
2+
, but augmented mitochondrial Ca
2+
 in the two cell 
lines which played key role to induce apoptosis leading to cell death. Curcumin inhibited the 
AGS cell proliferation in a time- and concentration-dependent manner (p<0.05) causing 34% 
decrease at 5 μmol/L, 51% at 10 μmol/L, and 92% at 25 μmol/L after 96 hours of treatment. It 
was interesting to note that when curcumin (10 μmol/L) was removed after a 24 hours 
exposure, the growth pattern of curcumin-treated AGS cells was similar to that of control 
cells, suggesting reversibility of curcumin on the progression of AGS cells [77].  
The combined therapy of Curcumin and 5-fluorouracil (5FU, a pyrimidine analog; it is a 
suicide inhibitor and works through irreversible inhibition of thymidylate synthase, Figure 4) 
inhibited the AGS cell proliferation considerably in comparison to either Curcumin or 5-FU 
monotherapy suggesting the synergistic effect of Curcumin with 5-FU against AGS human 
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gastric cancer cells. It was also found that 96 hours administration of Curcumin (10 μmol/L) 
in AGS gastric cancer cells, the G2/M phase fraction of the Curcumin treated cells was 60.5% 
in comparison to 22.0% of the control group, suggesting a G2/M block by Curcumin. 
Multidrug resistance (MDR) is a severe problem in cancer chemotherapy. It is often 
related with the overexpression of ATP-dependent drug efflux proteins belonging to the 
superfamily of ATP-binding cassette (ABC) transporters namely (i) P-glycoprotein (P-gp, 
170 kDa) encoded by the MDR1 gene and (ii) multidrug resistance-associated protein-1 
(MRP-1, 190 kDa) encoded by the MRP-1 gene. These proteins bind to and transport various 
structurally unrelated compounds to maintain their intracellular concentrations below 
cytotoxic levels [78, 79]. 
Vincristine (brand name, Oncovin, abbreviation: VCR, Figure 4) is a vinca alkaloid 
isolated from the plant Cantharanthus roseus. It is a coupled alkaloid of vindoline and 
cantharanthine, biosynthesized in the plant. Being a potent mitotic inhibitor it is one of the 
frontline cancer drugs and belongs to WHO‘s list of essential medicines [80]. The ability of 
Curcumin to act as a chemosensitizer to sensitize the vincristine (drug) resistant human 
gastric cancer cells SGC7901/VCR to undergo apoptosis was studied [81]. It increased the 
sensitivity of SGC7901/VCR cells to vincristine consistently with an increase in intracellular 
drug concentration by decreasing P-gp function and expression. It is known that P-
glycoprotein (P-gp) plays an important role to prevent cell death not only by removing 
(efflxing) drugs from the cell, but also by inhibiting the activation of proteases associated to 
initiate (caspase-8) [82] and to execute (caspase-3) apoptotic signaling [82, 83]. Treatment by 
Curcumin on drug-resistant SGC7901/VCR cells stimulated vincristine-induced caspase-3 
activation. P-gp was up-regulated in SGC7901/VCR cells, whereas it was suppressed, at least 
to some extent, after a 24 hours treatment with Curcumin (10 μmol/L). Resistant cells treated 
with 1 μmol/L vincristine itself showed 77% lower levels of caspase-3 activation relative to 
SGC7901 cells, but the activation of caspase-3 in the resistant cell line increased by 44% 
when cells were treated with vincristine accompanied by Curcumin. Taken together, 
Curcumin reversed the MDR of the human gastric carcinoma SGC7901/VCR cell line and it 
could be considered as a promising chemosensitizer of MDR in gastric cancer. 
N-nitroso-N-methylurea (NMU) is a strong carcinogen, mutagen, and teratogen. It holds 
the potential to alkylate the nucleobases in nucleic acids by transferring its methyl group, 
which eventually leads to AT:GC transition mutations. Curcumin treatment on NMU and 
saturated sodium chloride-induced gastric cancer in male Wistar rats was investigated [84]. 
At the initiation period Curcumin successfully reduced the gastric cancer through down-
regulation of phosphorylated IκBα and 8-OHdG expressions. Besides the above, Curcumin 
successfully demonstrated its potential as a chemopreventive agent in Phase I clinical trial in 
patients with high-risk or pre-malignant lesions of gastric cancer [85]. 
 
 
3.4. Colorectal Cancer (Colon Cancer) 
 
Colorectal cancer is the fourth leading cause of cancer-related mortality worldwide in 
2012 with a five-years prevalent of 10.9%. The molecular intricacies of colon tumors are not 
fully understood. In vitro studies in human colorectal carcinoma HCT-116 cell line [86] 
showed the overexpression of a few histone demethylases such as JMJD2A, JMJD2B and 
JMJD2C but not JMJD2D. Moreover, despite of close homology of JMJD2A-C, their 
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intracellular localizations were different. JMJD2A was mainly localized in cytoplasm and 
nucleus, JMJD2B preferred to be localized in nucleus only whereas JMJD2C was strongly 
attached with chromatin. The protein JMJD2C (also known as KDM4C) played crucial roles 
to develop tumor (HCT-116 cells) by complex formation with β-catenin (an oncoprotein) and 
promoting its up-regulation. JMJD2C also helped to up-regulate the growth stimulatory 
proteins FRA1, Cyclin D1 and survival factor Bcl-2. Curcumin exhibited its potential to 
reduce the activity of JMJD2 enzymes through down-regulation. It was proposed that 
Curcumin induced sustained activation of JNK, which in turn stimulated apoptosis as a result 
of inhibition of NFkB transcriptional activity in human colorectal carcinoma (HCT-116) cell 
line [87]. 
Later, the same authors reported that it was not essential for Curcumin to inhibit NF-κB 
for its anti-apoptotic effects rather other unidentified regulators [88] might be involved in cell 
death process. A study carried out by Wang et al. [89] revealed that neurotensin (an intestinal 
hormone that was potently released by fat ingestion) acted via the native high-affinity 
neurotensin receptor (NTR) increased the secretion and up-regulation of IL-8 in a 
concentration- and time-dependent manner. This activation implicated Ca
2+
-dependent 
protein kinase C, extracellular signal-regulated kinase-dependent activator protein-1, and 
extracellular signal-regulated kinase-independent nuclear factor-κB (Ca
2+
/PKC, ERK/ AP-1, 
and NF-κB) pathways. These effects eventually enhanced the HCT-116 cell proliferation and 
migration. Curcumin successfully inhibited gastrointestinal hormone (e.g., neurotensin)-
induced chemokine up-regulation and subsequent cell migration. It is known that the enzyme 
DNAtopoisomerase II alpha (TOP2A) is upregulated in several cancers and acts on 
RNApolymerase II transcription on chromatin templates. On the other hand, CTCF (also 
known as 11-zinc finger protein or CCCTC-binding factor, a multifunctional transcription 
factor) recruits the largest subunit of RNA polymerase II (LS Pol II) and this recruitment of 
LS Pol II is more pronounced in proliferating cells than in fully differentiated cells.  
As expression of imprinted genes is often altered in tumors, the therapeutic effect of 
Curcumin on transcription of the imprinted H19 gene was investigated [90] in HCT 116 and 
another human colon adenocarcinoma (SW 620) cell lines. It was concluded that Curcumin 
down-regulated the TOP2A and subsequently inhibited RNA polymerase II-dependent 
transcription and eventually - gene transcription was inhibited. 
Curcumin inhibited the proteasome and induced apoptosis in both HCT-116 and 
metastatic SW480 human colon adenocarcinoma cell lines [91]. This study confirmed 
proteasome as an important cellular target of Curcumin. In silico docking studies between 
proteasome and Curcumin showed that two carbonyl carbons of the Curcumin (Figure 1) 
were highly susceptible to a nucleophilic attack by the hydroxyl group of the N-terminal 
threonine of the proteasomal chymotrypsin-like (CT-like) subunit. As a result, Curcumin 
inhibited the proteasome activity in human colon cancer HCT-116 and SW480 cell lines 
which directed to accumulation of ubiquitinated proteins, several proteasome target proteins, 
and subsequent induction of apoptosis in vitro. The effect was confirmed in animal model 
through intragastric administration of Curcumin to ICR SCID mice bearing xenografts of 
colon cancer HCT-116 cells. The experiment resulted in significant inhibition of tumor 
growth because of proteasomal inhibition which repressed cell proliferation and stimulated 
cell death via apoptosis. It was reported that only 3–5% of all colorectal cancers are due to 
hereditary genetic defects and up to 25% of patients might have some degree of familiarity 
for this disease whereas majority of colorectal cancers take place in an erratic fashion without 
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any documented family history. In addition to genetic instability phenotypes such as 
chromosomal and microsatellite instability, epigenetic alterations that include DNA 
methylation modifications, histone alterations and variations in miRNA expression might be 
responsible for the initiation and progression of increasing incidences of colorectal cancers 
[92, 93]. The effect of Curcumin on DNA methylation of three colorectal cancer cell lines 
such as HCT116, HT29 (human colorectal adenocarcinoma) and RKO (human colon cancer) 
was studied [94]. It was found that Curcumin might exhibit its anti-cancer activity, at least in 
part, via epigenetic modulation of DNA methylation changed only in a subset of genes those 
were distinct from the generalized genomic hypomethylation related with amplified genomic 
instability in colorectal cancer cells. 
Autophagocytosis (or Autophagy, in Greek: auto means self and phagein means to eat) is 
a basic catabolic mechanism which involves the degradation of unnecessary or dysfunctional 
cellular components in cell via the actions of lysosomes. The breakdown of cellular 
components promotes cellular survival during starvation by maintaining cellular energy 
levels. Depending upon the state of the disease, autophagy may be a response to stress that 
promote survival whereas in other cases it appears to promote morbidity or cell death [95, 
96]. 
A study carried out by Mosieniak et al. with HCT-116 cell lines concluded that despite of 
its low bioavailability, Curcumin could demonstrate good anticancer activity because of 
cellular senescence of the cancer cells [97]. It was reported that the senescence of cancer and 
normal cells contained many common features and the senescence of HCT116 cells was 
correlated with the induction of autophagy. In the case of p53+/+ HCT116 cells, 
overexpression of the p53 and p21 proteins was observed whereas p53-independent induction 
of p21 was observed in p53-/- HCT116 cells. The correlation between autophagy and 
senescence was established by electron microscopy observations of autophagosomes, LC3-II 
up-regulation, punctue staining of LC3 and increased content of acidic vacuoles in the 
curcumin-treated cells. However, inhibition of autophagy, due to the reduced expression of 
Autophagy protein 5 (ATG5) by RNAi reduced the number of senescent cells promoted by 
curcumin, but did not lead to increased cell death. Another study targeted doublecortin-like 
kinase 1 (DCLK1), a cancer stem cell marker, to enhance anticancer activity of Curcumin.  
At optimum concentrations, curcumin significantly decreased expression levels of stem cell 
markers (DCLK1/CD44/ALDHA1/Lgr5/Nanog) in three-dimensional spheroid cultures and 
tumor xenograft models derived from colon cancer cells. However, Curcumin surprisingly 
induced proliferation and autophagic survival of a subset of DCLKl-positive cancer stem cells 
[98].  
Conversely, the combination of DCLK1-siRNA and Curcumin could intensely reverse 
the phenotype of cancer stem cells. The RNAi-mediated silencing of DCLK1 activated 
Curcumin-induced apoptotic cell death of colon cancer cells in vitro and in vivo. 
Cortactin (cortical actin binding protein CTTN, a monomeric protein located in the 
cytoplasm of cells), encoded by the CTTN/EMS1 gene, is a v-Src substrate localized with 
cortical actin at the plasma membrane and is up-regulated in several types of cancer [99].  
The phosphorylated form of cortactin (pTyr421) plays major role in cancer cell migration and 
invasion. It was shown that pTyr421-cortactin was up-regulated in colon cancer.  
Curcumin interacted with PTPN1 tyrosine phosphatases to rise its efficacy leading to 
dephosphorylation of pTyr421-CTTN. Curcumin considerably reduced the pTyr421-CTTN in 
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HCT116 cells and SW480 (adenocarcinoma of the colon) cells, but was ineffective in HT-29 
(human colorectal adenocarcinoma) cells.  
Altogether, Curcumin modulated the activity of PTPN1 phosphatase to reduce cortactin 
phosphorylation and interaction with CTNND1, and finally to reduce colon cancer cell 
migration [100]. Curcumin activated MAPKs including Erk1/2 and JNK and inhibited 
phosphatases 2A (PP2A) and 5 (PP5). Up-regulation of MAPK cascade induce ROS which 
ultimately led to p53-independent apoptosis in cancer cells [101]. 
Treatment with Curcumin destroyed wild-type p53 HCT-116 cells and mutant p53 HT-29 
cells in a concentration- and time-dependent fashion. Curcumin treatment also exhibited 




 HCT-116 cells, validating that curcumin-
induced cytotoxicity was independent of p53 status. Therefore, Curcumin holds the 
therapeutic potential to combat with the colorectal tumors those are resistant to conventional 
chemotherapy due to defects in p53 expression or function [102]. 
Curcumin treatment on other colorectal cancer cell lines was also investigated. Curcumin 
repressed the proliferation of HCT-15 (human colorectal adenocarcinoma) cells by inducing 
apoptosis in a time- and concentration-dependent manner [103]. The apoptotic pathway was 
proposed by activation of caspase-3, down-regulation of pre-mRNA processing factor 4B 
(PRP4B) and generation of ROS. Curcumin-induced inhibition of proliferation in HT-29 
(human colon adenocarcinoma) and Caco-2 (heterogeneous human epithelial colorectal 
adenocarcinoma) proceeded by repression of EGFR [104]. 
The process was initiated by the interruption of the ERK signal pathway by down-
regulating ERK and subsequently its activity was reduced. Accordingly the transcription 
factor early growth response-1 (Egr-1) was suppressed and Egr trans-activity was reduced 
which finally down-regulated the EGFR expression leading to inhibition of colon cancers 
(HT-29 and Caco-2) cell proliferation. 
Treatment with Curcumin could successfully inhibited the proliferation of human colon 
cancer (COLO 205) cells through apoptosis, in concentration- and time-dependent manner, by 
the generation of Ca
2+
 and ROS, followed by attenuation of the levels of mitochondria 
membrane potential and finally the activation of caspase-3 [105]. 
The same research group also reported that Curcumin attenuated the N-acetyltransferase 
(NAT) activity in a concentration-dependent manner in COLO 205 cells. Moreover Curcumin 
treatment also reduced the DNA adduct formation and down-regulated gene (NAT1) mRNA 
expression [106]. 
The treatment of colorectal cancer is challenging because of drug resistance. In particular, 
more than 15% patients are found to be resistant to 5-Fluorouracil (5-FU, Figure 4) derived 
chemotherapeutic agents. Accordingly, the colorectal tumor relapses in case of more than 
50% patients. Curcumin demonstrated promising chemosensitizing activity to sensitize DNA 
mismatch repair (MMR)-proficient 5-FU-resistant colon cancer cells HCT116R, 
HCT116+ch3R (complemented with chromosome 3) in high density 3D culture which 
resulted in improved fragmentation of colonospheres, increased apoptosis and related growth 
inhibition [107]. Curcumin drawn considerable interest to serve as radiosensitizer in 
colorectal cancer radiotherapy. Radio-resistance can be facilitated by constitutively active 
pro-survival signaling pathways or by inducible/acquired mechanisms in response to radiation 
therapy. The NF-κB activation was characterized as a mechanism of inducible radio-
resistance in colorectal cancer (HCT116, HT29, and SW620) cells. 
Complimentary Contributor Copy
Curcumin 23 
For the Curcumin-pretreated cells the resistance can be successfully overcome and better 
radiotherapeutic effect can be achieved [108]. Curcumin inhibited the proliferation and the 
post-irradiation clonogenic survival of colorectal cancer cells.  
It also down-regulated the radiation-induced NF-κB activation through inhibition of 
radiation-induced phosphorylation, repressing NF-κB-regulated gene products (Bcl-2, Bcl-xL, 
inhibitor of apoptosis protein-2, cyclooxygenase-2, and cyclin D1) and inhibition of Akt 
phosphorylation. 
Curcumin showed synergistic activity with various drugs/compounds against colorectal 
cancer cell lines. This activity can be summarized as shown in Table 3. 
Apart from the above discussion, the Phase I trial of oral Curcumin was carried out which 
advocated for its Phase II evaluation in the prevention or treatment of cancers outside the 
gastrointestinal tract [116]. A recent clinical pilot study aimed to quantify levels of 
curcuminoids in colorectal mucosa of patients after administration of oral curcumin [117] 
yielded promising results and recommended the regimen as safe, and patients support its use 
in long-term trials. 
 




 Mechanism of action Reference 
HT-29 5-FU 
Inhibition of COX-2 
expression. 
[109] 




Inhibition of NF-κB and Src 










Down-regulation of CD133, 
CD44, CD166 and ALDH. 
[112] 
HCT-116 Dasatinib Not known. [113] 
HCT-116 Resveratrol 
Inhibition of constitutive 
activation of EGFR and its 




2 and SW-480 
Celecoxib 
Inhibition of COX-2 and 
other non-COX-2 pathways. 
[115] 
*
See Figure 4. 
 
 
3.5. Breast Cancer 
 
The incidence of breast cancer (both sexes) was second highest among all cancers 
(11.9%) and it was the leading cause of mortality due to cancer among women worldwide 
(fifth for both genders) in 2012 [39]. Several research laboratories around the world have 
been engaged to investigate the pharmacological potential of Curcumin against different types 
of breast cancer. Curcumin could successfully inhibit the proliferation of human breast cancer 
MDA-MB-435 cells in a concentration- and time-dependent manner by accumulating the 
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cells in the G1 phase of the cell cycle. The overexpression of EZH2 in human breast cancer 
MDA-MB-435 cells caused poor prognosis in this type of cancer. The underlying molecular 
mechanism of Curcumin treatment was explained by the activation of the MAPK signaling 
pathway. Three major members of the MAPK family, the p38 kinase, JNK and ERK were 
stimulated to down-regulate the enhancer of zeste homolog 2 (EZH2) gene overexpression 
leading to proliferation of the cancer cells [118]. Activated cancer-associated fibroblasts 
(CAFs) or myofibroblasts facilitate the growth of tumor as well as develop drug-resistance in 
human breast cancer. Hence effective therapeutic regimen should be able to inhibit the 
paracrine effects of these supportive cells. Treatment with Curcumin on patient-derived 
primary breast CAF cells overexpressed p16
INK4A and other tumor suppressor proteins while 
inactivated the JAK2/STAT3 pathway. This repressed the alpha-smooth muscle actin  
(α-SMA) and consequently the cell migration/invasion was reduced [119]. Curcumin also 
down-regulated Lamin B1 and initiated DNA damage-independent senescence in 
proliferating but not inactive breast stromal fibroblasts. Curcumin-induced senescence was 
p16
INK4A
-dependent and occurred with no associated inflammatory secretory phenotype. 
Approximately 15% of all breast cancers are triple-negative breast cancer (TNBC).  
In TNBC, the reoccurrence of tumor rate is high with poor prognosis and low survival rate. 
TNBC is characterized by the lack expression of progesterone receptor (PR), estrogen 
receptor (ER) and epidermal growth factor receptor 2 (HER2/cerbB2/EGFR2) expression 
[120, 121]. Therefore, TNBC lacks effective targeted therapies. The only possible therapeutic 
option in the adjuvant or metastatic situation is chemotherapy but most unfortunately TNBC 
is often resistant to standard chemotherapeutic regimens. Consequently, TNBC has the worst 
prognosis and survival rate of all breast cancer subtypes. Curcumin demonstrated its ability to 
inhibit the proliferation of MDA-MB-231 TNBC cells inducing apoptosis in vitro by 
inhibiting the EGFR signaling pathway [122]. The level of apoptosis of the curcumin-treated 
(30 μmol/mL) group (26.34%) was significantly different from that of the control group 
(2.76%). All these findings suggest that further studies with Curcumin are required, 
particularly in this subset of breast cancer patients, for those proper treatment opportunities 
are very limited. The anti-breast cancer effect of Curcumin was also evaluated with three 
other TNBC cells such as MDA-MB-468 (MDA468), HCC1937, and HCC1806 by Nahta and 
co-workers [123]. Besides these, HER2-overexpressing SKBR3 cells, ERα (+) MCF7 human 
breast cancer cells, and non-transformed mammary epithelial MCF12A cell lines were also 
evaluated with Curcumin. The molecular mechanism was described by the DNA damage in 
TNBC cells along with phosphorylation, increased expression, and cytoplasmic retention of 
the BRCA1 protein. Moreover, Curcumin induced apoptosis and anchorage-independent cell 
growth (which is considered as a hall mark in cancer biology) and subsequent migration of 
TNBC cells. In case of non-transformed mammary epithelial MCF12A cells apoptosis and 
BRCA1 protein modulation were not observed which might be considered as target 
specificity of curcumin toward TNBC cells. 
To evaluate the anticancer effect of the dietary antioxidant Curcumin on mammary  
cells which are resistant to oxidative damage, human breast cancer cells ZR-75-1 were treated  
with Curcumin and CuSO4 in order to assess cell proliferation and GGTP  
(γ-glutamyltranspeptidase) activity. Curcumin demonstrated cytotoxicity toward ZR-75-1 
cells and down-regulated GGTP activity in a concentration-dependent manner. It induced 
apoptosis and exhibited antioxidant effect only on the copper-oxidized cells. Taken together, 
Curcumin inhibited the proliferation of human breast cancer ZR-75-1 cells under oxidative 
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stress through apoptosis [124]. In another study it was revealed that Curcumin induced anti-
proliferative effect on two human breast cancer cell lines (MDA-MB-231 and BT-483) in a 
concentration- and time-dependent manner via apoptosis [124]. The results showed that the 
expression of Cyclin D1 was down-regulated in MDA-MB-231 cells whereas CDK4 
expression was down-regulated in BT-483 breast cancer cells. On the other hand, MMP1 
mRNA expression was significantly down-regulated in both the breast cancer cells. 
Altogether it was concluded that Curcumin-induced anti-proliferative effect was due to 
suppression of NFκB inducing genes [125]. To investigate whether Curcumin-induced cell 
proliferation and apoptosis in human breast cancer MDA-MB-231 cell lines were associated 
with down-regulation of Notch1 gene expression as well as NF-κB suppression, the mRNA 
and protein expression of Notch1 and NF-κB were measured by RT-PCR and Western blot 
[126]. The results showed that the mRNA and protein levels of Notch1 and NF-κB were 
reduced considerably in concentration- and time-dependent manner (P < 0.05). From this 
observation it was concluded that the Notch-1 signaling pathway was mechanistically linked 
with NF-κB activity during curcumin-induced inhibition of cell growth and cell death through 
apoptosis in human breast cancer MDA-MB-231 cell lines. 
It was also supported that Curcumin-induced apoptosis in human breast cancer MCF-7 
cells was accompanied by an increase in p53 level as well as its DNA-binding activity 
followed by Bax expression at the protein level [127]. 
Human epidermal growth factor receptor 2 (HER2 or HER2/neu) is an oncogene and its 
overexpression plays a key role in the growth and progression of certain aggressive type of 
breast cancers with higher relapse rate, and increased mortality. It has become an important 
biomarker and therapeutic target of about 20-30% of breast cancer patients [128]. HER-2 is 
an important oncoprotein overexpressed in about 15-25% of breast cancers. It was 
hypothesized that the ability of curcumin to down-regulate HER-2 oncoprotein and inhibit the 
signal transduction pathway of PI3K/Akt, MAPK, and NF-κB activation may be important in 
the treatment of HER-2-overexpressed breast cancer. The therapeutic potential of Curcumin 
to down-regulate HER-2 oncoprotein was investigated in five human breast cancer cells: 
MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr (a herceptin resistant strain 
from SK-BR-3) in vitro. The HER-2-overexpressed BT-474 xenograft model was used for in 
vivo validation of Curcumin on HER-2-overexpressed breast cancer. Curcumin successfully 
reduced the cell proliferation in all the five tested breast cancer cell lines. The Western blot 
analysis showed that the phosphorylation of Akt, MAPK, and expression of NF-κB were 
reduced in BT-474 cells, but not in SK-BR-3-hr cells, after treatment with herceptin. When 
treated with curcumin, the HER-2 oncoprotein, phosphorylation of Akt, MAPK and 
expression of NF-κB were decreased in both BT-474 and SK-BR-3-hr cells. In the BT-474 
xenograft model, though not as much as herceptin, Curcumin effectually reduced the tumor 
size [129]. 
Circulating tumor cells (CTC) are present into the vasculature from a primary tumor and 
flow in the bloodstream. Therefore, CTCs can be considered as seeds for subsequent growth 
of additional tumors (metastasis) in distant organs, initiating a mechanism that is responsible 
for the vast majority of cancer-related deaths [130]. As stated earlier, invasion and metastasis 
are two serious problems for the prevention/treatment of cancer. The properties of circulating 
tumor cells (CTC) and cancer stem-like cells (CSC) are related with distant metastasis, but 
the mechanisms through which CSCs promote metastasis are not clear. It was reported that 
breast cancer cell lines with more stem-like properties display higher levels of microtentacles 
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(McTN), a type of tubulin-based protrusion of the plasma cell membrane that forms on 
detached or suspended cells and aid in cell reattachment. Curcumin promptly quenched 
McTN in breast CSC, preventing reattachment from suspension. 
Overall, a model in which breast CSCs with cytoskeletal alterations that promote McTNs 
can mediate attachment and metastasis but might be targeted by Curcumin as an anti-
metastatic strategy [131]. Chronic inflammation is a key risk factor for the growth and 
metastatic development of cancer. Curcumin inhibited the expression of the proinflammatory 
cytokines CXCL1 and -2 to reduce breast and prostate cancer metastases. From the 
microarray miRNA expression analysis it was found that Curcumin modulated the expression 
of a series of miRNAs, including up-regulation of miR181b, in metastatic breast cancer 
MDA-MB-231 cells where miR181b down-regulated the proinflammatory cytokines CXCL1 
and -2 through a direct binding to their 3'-UTR. Curcumin-induced up-regulation of miR181b 
in metastatic breast cancer cells inhibited metastasis formation in vivo in immune-deficient 
mice [132]. Another study in this field suggested that metastatic development in human 
mammary epithelial carcinoma MCF-7 cells was inhibited by Curcumin via the suppression 
of urokinase-type plasminogen activator by NF-κB signaling pathways [133]. 
MMP-9 is a major factor in cancer cell invasion. An invasion-related study in MCF-7 
human breast cancer cells [134] supported that Curcumin suppressed the TPA-induced MMP-
9 expression and subsequent cell invasion. 
The molecular mechanism involved Curcumin-induced inhibition of PKCα-dependent 
MMP-expression, down-regulation of NF-κB and reduction of AP-1 activation i.e. repression 
of the PKCα, MAPK and NF-κB/AP-1 pathway in MCF-7 cells. 
It has been found that breast cancer is often associated with obesity. Most probably the 
relation between these two factors is mediated by adipokines. Visfatin [Nicotinamide 
phosphoribosyltransferase (NAmPRTase or Nampt) also known as pre-B-cell colony-
enhancing factor 1 (PBEF1)] is an adipokine, that is localized to the bloodstream and has 
various functions. The protein visfatin has recently been shown to be related to the 
development and progression of breast cancer. 
Consequently, suppression of the gene visfatin might be a novel strategy to fight against 
breast cancer. The influence of Curcumin on visfatin gene suppression was investigated [135]. 
It was found that the mRNA and protein levels of visfatin were down-regulated by Curcumin 
in human breast cancer MDA-MB-231, MDA-MB-468, and MCF-7 cell lines. In addition, the 
activity of constitutive nuclear factor (NF)-κB was reduced. 
Taken together, visfatin could enhance the invasion of breast cancer cells which was 
down-regulated by Curcumin. Furthermore, visfatin knockdown by siRNA led to the 
reduction of cancer cell invasion. Curcumin treatment could impose anti-migratory activity in 
human breast cancer MDA-MB-231 cells [136]. It inhibited proliferation and migration by 
increasing the Bax to Bcl-2 ratio and decreasing NF-κBp65 expression. Integrin (α6β4) is a 
laminin adhesion receptor with an established role in the invasion and migration of cancer 
cells. Curcumin successfully decreased the integrin (α6β4)-dependent breast cancer cell 
motility and invasion in a dose-dependent manner without affecting apoptosis in MDA-MB-
435/β4 (β4-integrin transfectants) and MDA-MB-231 breast cancer cell lines [137]. 
Maspin (mammary serine protease inhibitor) can suppress tumor growth and metastasis 
in vivo and tumor cell motility and invasion in vitro in breast cancer. The maspin expression 
in Curcumin-treated MCF-7 (wild type p53) at transcription and translation levels was 
analyzed by RT-PCR, immunofluorescence, and Western blotting. 
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The results showed a correlation of maspin expression with p53 and Bcl-2 levels. 
Curcumin inhibited cell proliferation by inducing apoptosis and up-regulation of maspin gene 
expression was observed in MCF-7 cells. 
These findings were further correlated with the up-regulation of p53 protein and down-
regulation of Bcl-2, suggesting maspin mediated apoptosis in MCF-7 cancer cells [138]. The 
chemopreventive activity of Curcumin in transformed breast cells was investigated [139]. 
Curcumin inhibited H-ras-induced invasive phenotype in MCF10A human breast epithelial 
cells (H-ras MCF10A); repressed MMP-2 and exerted cytotoxic effect on H-ras MCF10A 
cells in concentration-dependent manner. The apoptotic cell death involved significant down-
regulation of Bcl-2 and up-regulation of Bax. 
Curcumin treatment resulted in the generation of ROS in H-ras MCF10A cells. In brief, 
the results supported that curcumin inhibited invasion and induced apoptosis in the 
transformed breast cancer H-ras MCF10A cells. 
Drug-synergy has also been demonstrated by Curcumin with several other drugs against 
breast cancer cell lines. A brief description is outlined below (Table 4): 
 




 Mechanism of action Reference 
MCF-7 
LY290042 (PI3K 
inhibitor, Figure 4) 
Apoptotic cell death via Akt 













MCF-7 Mitomycin C 
Inhibition of GRP58-
mediated DNA cross-linking 





MDA-MB-231 Taxol (Paclitaxel) 
Inhibition of paclitaxel-
induced activation of NF-κB 
and potentiation of the 









See Figure 4. 
**





Aside from the previous discussion, anticancer effect of Curcumin was evaluated for 
many other types of cancer. Some representative examples are summarized in Table 5. 
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Conclusion and Future Aspects 
 
Curcumin is a non-toxic, cheap and easily available natural polyphenol with high 
medicinal and commercial demands. Many costly products can be derived from Curcumin. 
For example, Curcumin can easily be converted to vanillin through a single-step conversion 
[172]. 
However, a huge number of preclinical and early-phase clinical studies undoubtedly 
confirmed that Curcumin, the golden spice [173] from India, is safe with vast potential of 
becoming an effective drug for several human diseases including chronic inflammation and 
cancer. Moreover, the results of clinical trials are under progress in different parts of the 
world. A serious concern regarding pharmacological application of Curcumin is its poor 
pharmacokinetics (PK) profile. The bioavailability of Curcumin is low because of poor 
absorption, rapid elimination and/or low target organ concentration. This is due to the reason 
that Curcumin is conjugated when it is absorbed through the intestine, consequently free 
curcumin is present at extremely low level in the target organ. 
Moreover, in biological system it is rapidly converted to its metabolites. Nevertheless, 
Curcumin is non-toxic with a dose of 8g/day is well tolerable and 12g/day may cause minor 
adverse effects like diarrhea, headache, yellowish stools and rashes etc. 
 
Table 5. Anticancer activity of Curcumin on different types of cancer 
 
Cancer type/Cell Description/Mechanism of action Reference 
Oral 
SAS and SAS/luc 
(transfected with luc gene) 
SAS cancer cell proliferation was greatly inhibited in vitro 




Detroit 562 and HONE-1 
Inhibition of cell proliferation inducing apoptosis via 
caspase-3-dependent pathway. 
[146] 
NPC/CNE2 Dark cytotoxicity and photocytotoxicity: Apoptosis [147] 
CNE-2Z 
Inhibit cell proliferation by apoptosis. Alters expression of 
proteins in the ERK-1/2 signaling pathway. 
[148] 
Oesophageal (Esophageal) 
OE19, OE21, OE33 and 
KYSE450 
Inhibition of cell proliferation via non-apoptotic form of cell 
death. Caspase-3 activation was detected in two out of four 
cell lines (OE21 and OE33), but was a minor event. 
[149] 





Apoptosis through caspase 3 activation. 
Down-regulation of Cyclin D1 
Down-regulate the expressions of Notch-1 specific 
microRNAs, miR-21 and miR-34a, and upregulation of 




Apoptosis by regulating the ratio of Bcl-2/Bax and 
activating the expression of cleaved caspase-3. 
[151] 
HAG-1 
G2/M arrest and apoptosis through multiple mechanisms 
involving enhanced mitogen-activated protein (MAP) 






Cancer type/Cell Description/Mechanism of action Reference 
Pancreas 
MIA PaCa-2 
Inhibition of cell proliferation inducing apoptosis. 
Downregulation of the transcription nuclear factor      NF-κB 
and NF-κB-regulated gene products 
[153] 
BxPC-3 and MIA PaCa-2 
Inhibition of cell proliferation inducing apoptosis. 
Activation of TNFR, CASP 8, CASP3, BID, BAX, and 




Downregulation MMP-2 expression and activity and 
expression of integrin receptors, FAK, and MT1-MMP to 
almost background levels. MMP-2 (but not MMP-9) mRNA 
expression was abolished. 
[155] 
Cervix 
KB-V1 Duel modulation of MDR1 expression and Pgp function [156] 
HeLa 
Down-regulate HPV18 transcription as well as the AP-1 
binding activity. 
Reverse the expression dynamics of c-fos and fra-1. 
[157] 
Ovary 
HEY, OVCA429, OCC1, 
SKOV3 
Inhibition of cell proliferation inducing p53-independent 
apoptosis that involved p38 MAPK activation, ablation of 
prosurvival Akt signaling, and reduced expression of the 
antiapoptotic proteins Bcl-2 and surviving. 
[158] 
OVCA 420 and OVCA 
429 
Suppression of JAK-STAT signaling via activation of PIAS-




LNCaP and PC-3 
Apoptosis through Bax translocation to mitochondria and 
caspase activation. 
[160] 
DU145 and PC-3 
Tumor necrosis factor-related apoptosis-inducing ligand 





Dose-dependently induced apoptosis of NTera-2 cells by 
reducing FasL expression and Bcl-2-to-Bax ratio, and 
activating caspase-9, -8 and -3. 




Induced apoptosis through the production of ROS, and 
the down-regulation of Bcl-xL and inhibitor of apoptosis 
protein (IAP) in Caki cells. 
Enhanced dual PI3K/Akt and mTOR inhibitor NVP-
BEZ235-induced apoptosis in human renal carcinoma Caki 
cells through down-regulation of p53-dependent Bcl-2 
expression and inhibition of Mcl-1 protein stability. 
[163] 
ACHN 
Induced apoptosis. Up-regulation of IκB, down-regulation of 
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Table 5. (Continued) 
 
Cancer type/Cell Description/Mechanism of action Reference 
Brain 
Glioma 





FTC-133 cell invasion was inhibited via down-regulation of 
PI3K/Akt signaling pathway. 
[166] 
K1 
Metastasis of K1 papillary thyroid cancer cells was inhibited 









Constitutive activation of nuclear factor-κB and IκBα kinase 
in human multiple myeloma cells was down-regulated, 





Apoptosis via simultaneously targeting Akt/mTOR and 
RAF/MEK/ERK survival signaling pathways. 
[170] 
JURKAT Caspase mediated apoptosis by disrupting the redox balance. [171] 
 
On the other hand, curcumin demonstrated diverse anticancer properties in vitro, ex vivo 
and in vivo as well as in clinical trials by inducing a variety of biological pathways involved 
in apoptosis, tumor proliferation, chemoprevention, chemo- and radiosensitization, tumor 
invasion, metastasis and angiogenesis. Curcumin can be an effective adjunct in treating solid 
organ tumors due to its properties of regulating oncogenes like p53, egr-1, c-myc, Bcl- XL, 
etc.; transcription factors like NF-kB, STAT-3, β-catenin and AP-1; growth factors (EGF, 
PDGF, and VEGF); protein kinases like MAPK, Cyclin D1, CDKs, Akt, PKC; and enzymes 
like COX, LOX, MMP and many others. Based on its huge therapeutic aspects several active 
investigations are going on to overcome the ADME-related drawbacks by introducing new 
and novel formulation and route of administration to achieve the highest therapeutic level. It 
is highly expected that curcumin will become an effective cancer drug in future with novel 
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